updated 9/7/2010 8:16:05 AM ET 2010-09-07T12:16:05

CHATSWORTH, Calif., Sept. 7, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostic systems and consumables for use in hospitals and commercial laboratories worldwide and provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the UBS annual Global Life Sciences Conference at 2:30 p.m. Eastern time on Monday, September 20, 2010 at the Grand Hyatt Hotel in New York City.

Mr. Garcia will also be available for one-on-one meetings with institutional investors at the conference on Monday, September 20 and Tuesday, September 21. Investors interested in scheduling a one-on-one meeting are asked to contact their UBS sales rep.

A webcast of Mr. Garcia's presentation will be available live and by replay, and can be accessed at www.proiris.com/investors/Webcasts_and_Presentations.php .  A replay of the presentation will be available approximately three hours following the live presentation and will be archived for 14 days.

About IRIS International

IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,800 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company recently acquired a high complexity CLIA-certified molecular pathology laboratory offering differentiated, high value molecular diagnostic services in the rapidly growing field of personalized medicine. The laboratory provides a direct commercial channel for the Company's NADiA®ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com .

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.71%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com